# APTN-101

Source: https://onco.cc/drugs/aptn-101/  
OnCo record `aptn-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

APTN-101 is a two-armed antibody from Adaptin Bio that steers a patient's own T cells against brain tumour cells carrying a faulty growth receptor. It is in a first trial in people with glioblastoma at Duke University.

## Summary

APTN-101 is Adaptin Bio's EGFRvIII x CD3 bispecific (BRiTE). The FDA accepted an investigator-initiated IND for a single-dose trial in May 2023 and a multi-dose amendment in October 2025; institutional review board approval for the multi-dose trial in glioblastoma came in March 2026, and Duke University opened the investigator-initiated phase 1 trial, "A Phase I Study of hEGFRvIII-CD3 bi-scFv (BRiTE) in Patients with WHO Grade IV Malignant Glioma", in August 2026.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: hEGFRvIII-CD3 bi-scFv; EGFRvIII BRiTE
- Tags: pipeline
- Code: APTN-101
- Modality: Bispecific T cell engager (EGFRvIII x CD3)
- Mechanism: A fully human bispecific single-chain antibody that binds EGFRvIII, a mutant form of EGFR found on tumour cells, and CD3 on T cells, redirecting the patient's T cells to kill the tumour; Adaptin Bio's BRiTE approach uses activated T cells to carry it into the brain.

## Sources

- SEC: Adaptin Bio Form S-1, August 2026: https://www.sec.gov/Archives/edgar/data/1938571/000121390026095034/ea0303043-s1_adaptin.htm

## Connected records

- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [Adaptin Bio](https://onco.cc/companies/adaptin-bio/)
- terms: [EGFRvIII](https://onco.cc/terms/egfrviii/)

---
JSON: https://onco.cc/api/v1/entities/aptn-101.json